Oruka Therapeutics Inc. (ORKA)
ORKA trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/907654/000095017024009809/0000950170-24-009809-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ORKA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000907654 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$5.3M |
| Operating income | -$7.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $37.4M |
| Total assets | $37.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $191.5M cash; operating cash flow -$30.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 67,822,359 (2026-10-31); 48,409,232 a year earlier; 14,410,143 three years earlier. 3y figure adjusted for splits (1-for-12 overall). | Cover page 2026-10-31 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2024-09-03 | Source 2024-09-03 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-08-28 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $333.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$50.0M | -$44.3M | $191.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$41.2M | -$33.1M | $268.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$31.8M | -$23.6M | $49.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$29.6M | -$22.6M | $46.9M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | Not filed | -$30.3M | -$21.6M | $91.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$24.6M | -$23.1M | $65.4M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$21.0M | -$20.9M | $83.6M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q3 2024 2024-09-30 | Not filed | -$28.6M | Not filed | $410.9M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B5 | 2026-08-28 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-12 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-09 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-26 |
| Latest proxy PROXY STATEMENT | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.4% |
| 1 month | +34.7% |
| 3 months | -2.6% |
| Year to date | +247.6% |
| 1 year | +299.4% |
| From 52-week high | -6.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LNTH | Lantheus Holdings Inc. | $101.72 | +0.13% | $6.7B |
| NEOG | Neogen Corporation | $10.88 | -3.12% | $2.4B |
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| IDXX | IDEXX Laboratories Inc. | $700.65 | -0.51% | $55.2B |
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier